Crescent Biopharma (CBIO) Return on Capital Employed (2014 - 2026)
Crescent Biopharma (CBIO) reported Return on Capital Employed of 79.38% for Q1 2026, up 16476.0% year-over-year from N/an in Q1 2025, and up 20.32% on a QoQ basis from 99.62% in Q4 2025.
Crescent Biopharma (CBIO) has 13 years of Return on Capital Employed data on file, last reported at 79.38% in Q1 2026.
- Quarterly Return on Capital Employed rose 16476.0% year-over-year to 79.38% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 79.38% (up 16476.0% YoY) and the FY2025 annual result came in at 149.81%, down 2004.0% from the prior year.
- Return on Capital Employed improved to 79.38% in Q1 2026 per CBIO's latest filing, from 99.62% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 61.41% in Q3 2025 and bottomed at 257.39% in Q4 2024.
- The 5-year median for Return on Capital Employed is 97.6% (2022), against an average of 119.38%.
- The widest annual swing landed in 2024, when Return on Capital Employed sank 16481 bps; it then soared 16476 bps in 2026.
- Tracing CBIO's Return on Capital Employed over 5 years: stood at 105.33% in 2022, then climbed by 12 bps to 92.58% in 2023, then slumped by 178 bps to 257.39% in 2024, then soared by 61 bps to 99.62% in 2025, then grew by 20 bps to 79.38% in 2026.
- Per Business Quant, the three latest CBIO Return on Capital Employed figures stand at 79.38% (Q1 2026), 99.62% (Q4 2025), and 61.41% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 20.34% |
| 10 | Crescent Biopharma | 569.36 Mn | 380.20 Mn | - | -79.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -79.38% |
| Dec 31, 2025 | -99.62% |
| Sep 30, 2025 | -61.41% |
| Jun 30, 2025 | -84.78% |
| Mar 31, 2025 | -244.14% |
| Dec 31, 2024 | -257.39% |
| Sep 30, 2024 | -214.12% |
| Jun 30, 2024 | -163.80% |
| Mar 31, 2024 | -114.46% |
| Dec 31, 2023 | -92.58% |
| Sep 30, 2023 | -78.85% |
| Jun 30, 2023 | -66.77% |
| Mar 31, 2023 | -81.46% |
| Dec 31, 2022 | -105.33% |
| Sep 30, 2022 | -102.75% |
| Jun 30, 2022 | -97.60% |
| Mar 31, 2022 | -84.96% |
| Dec 31, 2021 | -71.03% |
| Sep 30, 2021 | -57.83% |
| Jun 30, 2021 | -47.94% |
| Mar 31, 2021 | -44.51% |
| Dec 31, 2020 | -38.38% |
| Sep 30, 2020 | -35.47% |
| Jun 30, 2020 | -34.32% |
| Mar 31, 2020 | -35.20% |
| Dec 31, 2019 | -37.60% |
| Sep 30, 2019 | -34.68% |
| Jun 30, 2019 | -31.65% |
| Mar 31, 2019 | -27.20% |
| Dec 31, 2018 | -24.51% |
| Sep 30, 2018 | -20.69% |
| Jun 30, 2018 | -17.92% |
| Mar 31, 2018 | -21.25% |
| Dec 31, 2017 | -29.76% |
| Sep 30, 2017 | -29.20% |
| Jun 30, 2017 | -43.89% |
| Mar 31, 2017 | -91.66% |
| Dec 31, 2016 | -82.11% |
| Sep 30, 2016 | -69.81% |
| Jun 30, 2016 | -75.29% |
| Mar 31, 2016 | -34.06% |
| Dec 31, 2015 | -28.82% |
| Sep 30, 2015 | -21.70% |
| Jun 30, 2015 | -22.34% |
| Mar 31, 2015 | -26.96% |
| Dec 31, 2014 | -20.87% |
| Sep 30, 2014 | -12.63% |
| Jun 30, 2014 | -7.79% |
| Mar 31, 2014 | -55.70% |